Verastem Inc
NASDAQ:VSTM
Verastem Inc
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.
First Full Quarter Revenue: Net product revenue for AVMAPKI FAKZYNJA CO-PACK was $11.2 million in the third quarter, marking a strong first full quarter of commercial launch and surpassing company expectations.
Launch Momentum: The initial commercial adoption has accelerated, with consistent uptake from both academic centers and community oncologists and high engagement from top health care organizations.
Clinical Progress: Enrollment was completed for two major studies—RAMP-205 (first-line pancreatic cancer) and RAMP-301 (confirmatory Phase III in recurrent LGSOC), with only a modest increase in RAMP-301 enrollment recommended by the IDMC.
Reimbursement & Access: Reimbursement has not been a barrier, payer coverage now exceeds 80%, and time to fill prescriptions is about 12 to 14 days, with a balanced commercial and Medicare payer mix.
Pipeline Update: The VS-7375 KRAS G12D inhibitor program reported promising initial safety and tolerability data, with no dose-limiting toxicities and minimal gastrointestinal side effects.
Financial Position: The company ended the quarter with $137.7 million in cash and investments, providing runway into the second half of 2026.
